Retatrutide
Also known as LY3437943, Triple-G
Investigational triple GIP/GLP-1/glucagon receptor agonist.
- Category
- fat loss
- Route
- subq
- Documented dose
- 500–12000 mcg
- Typical frequency
- Once weekly
- Half-life
- ~6 days
- Common vial sizes
- 5 mg, 10 mg, 20 mg
- Regulatory status
- Investigational; not approved.
What it does
An investigational "triple agonist" that hits three metabolic receptors at once — GLP-1, GIP and glucagon. The glucagon arm also raises energy burn, not just lowers appetite. What people look into it for: • The largest average weight loss reported in this drug class so far in trials • Strong appetite suppression and reduced food cravings • Blood-sugar control and reduced liver fat It is still in clinical trials and is not approved anywhere, so long-term safety is not established.
Mechanism
Triple agonism adds glucagon-receptor-driven energy expenditure to incretin effects.
Storage — lyophilised
Refrigerate 2-8C, protect from light.
Storage — reconstituted
Refrigerate 2-8C, use within ~28 days.
Reconstitution notes
Research-grade vials only; strength verification is essential.
Commonly reported side effects
- Nausea
- Vomiting
- Increased heart rate
- Diarrhoea
Contraindications noted
- Pregnancy
- Thyroid C-cell tumour history
- Uncontrolled cardiovascular disease
Research notes
Still in clinical trials; no approved human product exists.
Track this properly
Work out syringe units with the free calculator, or set up a full schedule in about a minute.
Reference information only, not medical advice. See our medical disclaimer.